SCHEMBL3000256

SCHEMBL3000256

COC(=O)C1=C(C)Nc2nnnn2C1c1ccc(-c2ccc(OC)cc2)s1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.62
HPGD P15428 4/20 0.62
HTT P42858 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.58
NPSR1 Q6W5P4 3/20 0.53
HSD17B10 Q99714 1/20 0.48
THRB P10828 1/20 0.47
PKM P14618 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
MAPK1 P28482 1/20 0.47
CYP2C19 P33261 1/20 0.47
LMNA P02545 3/20 0.46
MAPT P10636 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999401 0.82 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2NPSR1
SCHEMBL3269150 0.77 ALDH1A1 (1.00) ALDH1A1HPGDHTTSMN1; SMN2NPSR1
SCHEMBL3005825 0.74 HPGD (0.78) ALDH1A1HPGDHTTSMN1; SMN2NPSR1
SCHEMBL4263306 0.70 ALDH1A1 (0.77) ALDH1A1HPGDHTTSMN1; SMN2NPSR1
SCHEMBL3003501 0.70 ALDH1A1 (0.60) ALDH1A1HPGDHTTSMN1; SMN2NPSR1
SCHEMBL2999707 0.70 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2NPSR1HSD17B10PKM
SCHEMBL2995959 0.69 ALDH1A1 (0.59) ALDH1A1HPGDHTTSMN1; SMN2NPSR1
SCHEMBL3004523 0.69 ALDH1A1 (0.55) ALDH1A1HPGDHTTNPSR1HSD17B10
SCHEMBL2990618 0.69 ALDH1A1 (0.53) ALDH1A1HPGDHTTSMN1; SMN2NPSR1
SCHEMBL2993859 0.68 ALDH1A1 (0.51) ALDH1A1HPGDHTTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045428-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2015-06-02 US disclosed
US-8716319-B2 Substituted heterocyclic compounds GILEAD SCIENCES, INC. (US) 2014-05-06 US disclosed
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-12-05 US disclosed
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD PALO ALTO, INC. (US) 2010-08-05 US disclosed
WO-2010002483-A1 OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2010-01-07 WO disclosed
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS CV THERAPEUTICS, INC. 2009-07-16 US disclosed
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS GILEAD SCIENCES, INC. 2009-01-08 US disclosed
WO-2009006580-A1 OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS CV THERAPEUTICS, INC. (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197684-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885HPGD 280/4885HTT 259/4885
US-20130324525-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885HPGD 280/4885HTT 259/4885
US-20090181986-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885HPGD 280/4885HTT 259/4885
US-20090012103-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS NQO1, GPR119, GLP1R ALDH1A1 274/4885HPGD 280/4885HTT 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.